Cefuroxime: Difference between revisions
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
==Category== | ==Category== | ||
[[Cephalosporins, second generation. | [[Cephalosporins]], second generation. | ||
==US Brand Names== | ==US Brand Names== | ||
Revision as of 23:31, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
Overview
Cefuroxime is a parenteral second-generation cephalosporin antibiotic. This antibiotic was discovered by the Glaxo company, now GlaxoSmithKline, and it was first marketed in 1978 as Zinacef. Zinacef was approved by the U.S. Food and Drug Administration on Oct 19, 1983. The generic form of cefuroxime is also called "Ceftin". The 17-year patent for this antibiotic has now expired in the United States, hence the patent "rights" to produce this medication are now irrelevant.
In the United States this antibiotic is also sold as "Zinacef" by Covis Pharmaceuticals
Category
Cephalosporins, second generation.
US Brand Names
CEFUROXIME®,ZINACEF®,KEFUROX®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | Compatibility and Stability | How Supplied | Labels and Packages
References
http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/50643s11lbl.pdf